ZAI LAB LIMITED Production Related Impairments or Charges
ZAI LAB LIMITED (ZLAB) reported Production Related Impairments or Charges of $5.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProductionRelatedImpairmentsOrCharges · last filed 2026-08-06
- ZAI LAB LIMITED production related impairments or charges for the quarter ending 2026-06-30 was $5.90M, a 1866.67% increase year-over-year.
- ZAI LAB LIMITED production related impairments or charges for the quarter ending 2026-03-31 was $200.00K.
- ZAI LAB LIMITED production related impairments or charges for the quarter ending 2025-12-31 was $11.40M.
- ZAI LAB LIMITED production related impairments or charges for the quarter ending 2025-09-30 was $600.00K.
- ZAI LAB LIMITED production related impairments or charges for fiscal 2025 was $12.30M, a 1437.50% increase from fiscal 2024.
- ZAI LAB LIMITED production related impairments or charges for fiscal 2024 was $800.00K, a 20.00% decline from fiscal 2023.
- ZAI LAB LIMITED production related impairments or charges for fiscal 2023 was $1.00M, a 100.00% increase from fiscal 2022.
- ZAI LAB LIMITED production related impairments or charges for fiscal 2022 was $500.00K, a 64.29% decline from fiscal 2021.
| Period end | Production Related Impairments or Charges 3 month | Production Related Impairments or Charges 6 month | Production Related Impairments or Charges 9 month | Production Related Impairments or Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.90M 10-Q · filed 2026-08-06 | $6.10M 10-Q · filed 2026-08-06 | $17.50M derived: sum of 3 quarters · filed 2026-08-06 | $18.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-07 | $11.60M derived: sum of 2 quarters · filed 2026-05-07 | $12.20M derived: sum of 3 quarters · filed 2026-05-07 | $12.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.00M derived: sum of 2 quarters · filed 2026-02-26 | $12.30M derived: sum of 3 quarters · filed 2026-08-06 | $12.30M 10-K · filed 2026-02-26 |
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-06 | $900.00K derived: sum of 2 quarters · filed 2026-08-06 | $900.00K 10-Q · filed 2025-11-06 | $900.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-06 | $300.00K 10-Q · filed 2026-08-06 | $300.00K derived: sum of 3 quarters · filed 2026-08-06 | $300.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $700.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $700.00K derived: sum of 3 quarters · filed 2026-02-26 | $800.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $700.00K derived: sum of 2 quarters · filed 2025-11-06 | $800.00K 10-Q · filed 2025-11-06 | $1.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $700.00K 10-Q · filed 2025-08-07 | $800.00K 10-Q · filed 2025-08-07 | $1.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $300.00K derived: sum of 2 quarters · filed 2026-02-26 | $400.00K derived: sum of 3 quarters · filed 2026-02-26 | $600.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $400.00K derived: sum of 2 quarters · filed 2026-02-26 | $600.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-12 | $300.00K derived: sum of 2 quarters · filed 2024-11-12 | $700.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-06 | $600.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $500.00K 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $1.40M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |